• OPEN AN ACCOUNT
Indian Indices
Sensex
83,371.98 -198.37
( -0.24%)
Global Indices
Nasdaq
49,379.59 -83.86
(-0.17%)
Dow Jones
6,960.70 -4.77
(-0.07%)
Hang Seng
53,565.61 -370.56
(-0.69%)
Nikkei 225
10,219.48 -19.46
(-0.19%)
Forex
USD-INR
90.32 0.07
(0.08%)
EUR-INR
104.98 -0.13
(-0.12%)
GBP-INR
121.10 -0.20
(-0.16%)
JPY-INR
0.57 0.00
(0.21%)

EQUITY - MARKET SCREENER

Industry :  
BSE Code
ISIN Demat
Book Value()
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
EPS(TTM)
Face Value()
Div & Yield %
 

Alembic Pharma receives USFDA approval for Travoprost ophthalmic solution
Dec 18,2025
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Travatan Z Ophthalmic Solution, 0.004%, marketed by Sandoz Inc. Travoprost ophthalmic solution is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

According to IQVIA, Dasatinib tablets have an estimated market size of US$ 61 million for the 12 months ending September 2025.

With this approval, Alembic has a cumulative total of 232 ANDA approvals from the USFDA, including 212 final approvals and 20 tentative approvals.

Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world.

The company’s consolidated net profit jumped 20.40% to Rs 184.71 crore in Q2 FY26, compared to Rs 153.41 crore posted in Q2 FY25. Revenue from operations grew 15.90% year on year (YoY) to Rs 1,910.15 crore in Q2 September 2025.

Shares of Alembic Pharmaceuticals shed 0.34% to Rs 844 on the BSE.